Notice2022-06427
Prescription Drug User Fee Rates for Fiscal Year 2022; Correction
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
March 28, 2022
Issuing agencies
Health and Human Services DepartmentFood and Drug Administration
Abstract
The Food and Drug Administration (FDA) is correcting a notice entitled "Prescription Drug User Fee Rates for Fiscal Year 2022" that appeared in the Federal Register of August 16, 2021. The document announced the Fiscal Year 2022 fee rates for the Prescription Drug User Fee Act. The document published with errors. The errors did not have an impact on the previously published user fee rates but are corrected in this document for clarity.
Full Text
<html>
<head>
<title>Federal Register, Volume 87 Issue 59 (Monday, March 28, 2022)</title>
</head>
<body><pre>
[Federal Register Volume 87, Number 59 (Monday, March 28, 2022)]
[Notices]
[Page 17300]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2022-06427]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2021-N-0709]
Prescription Drug User Fee Rates for Fiscal Year 2022; Correction
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice; correction.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is correcting a notice
entitled ``Prescription Drug User Fee Rates for Fiscal Year 2022'' that
appeared in the Federal Register of August 16, 2021. The document
announced the Fiscal Year 2022 fee rates for the Prescription Drug User
Fee Act. The document published with errors. The errors did not have an
impact on the previously published user fee rates but are corrected in
this document for clarity.
FOR FURTHER INFORMATION CONTACT: Misbah Tareen, Office of Financial
Management, Food and Drug Administration, 4041 Powder Mill Rd., Rm.
61077A, Beltsville, MD 20705-4304, 301-796-3997.
SUPPLEMENTARY INFORMATION: In the Federal Register of August 16, 2021
(86 FR 45732), appearing on page 45736 in FR Doc. 2021-17505, the
following corrections are made:
1. In the second column, in the last sentence of the third
paragraph under ``D. FY 2022 Statutory Fee Revenue Adjustments for
Operating Reserve'', ``both user fee funds available for obligation
$126,873,636 and funds that are considered unavailable due to a lack of
appropriations $98,850,995'' is corrected to read ``user fee funds
considered unavailable due to a lack of appropriations $78,850,995,
additional fee funds that are available for obligation but set aside
for future year refunds as a matter of prudent operations $20,000,000,
and carryover net of unavailable funds and the set-aside
$126,873,636.''
2. The fourth footnote is corrected by removing the text and
replacing it with: ``In recent PDUFA Annual Financial Reports, the
category ``unavailable for use'' has been used to refer both to (1) fee
funds that are considered unappropriated and (2) appropriated fee funds
the Agency has maintained to provide for any refunds. FDA intends to
discontinue use of the category ``unavailable for use'' in forthcoming
reports to better reflect the difference between these line items and
improve the clarity of its reporting. Although certain amounts have
been maintained for future refunds as a matter of prudent operations,
these amounts are considered appropriated and are available for
obligation.''
3. In the second column, in the fifth paragraph under ``D. FY 2022,
Statutory Fee Revenue Adjustments for Operating Reserve'', sentences 4
through 7 are corrected by removing the text and replacing it with
``FDA has decided to make an available operating reserve adjustment
that is intended to increase the amount of available funds to
approximately 8 weeks by the end of FY 2022, representing the low end
of the 8- to 10-week range while mitigating the impact on fee amounts.
FDA estimates the cost of operations per week is $22,144,672. Before
the operating adjustment, the estimated end of year FY 2022 available
operating reserve is $145,677,240, which equates to about 6\1/2\ weeks
of available operating reserves. Adding the FY 2022 operating reserve
adjustment of $39,402,923 to this amount is expected to provide
approximately 8 weeks of available operating reserve, or $185,080,162
(including $20,000,000 in available fee funds maintained for any future
refunds), and a total carryover of operating reserves (including
unavailable funds) of $263,931,157.''
Dated: March 21, 2022.
Andi Lipstein Fristedt,
Deputy Commissioner for Policy, Legislation, and International Affairs,
U.S. Food and Drug Administration.
[FR Doc. 2022-06427 Filed 3-25-22; 8:45 am]
BILLING CODE 4164-01-P
</pre></body>
</html>Indexed from Federal Register on March 28, 2022.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.